Pfizer's Obesity Drug Shows 16% Weight Loss In Phase 2b Study

Pfizer reported Phase 2b study results for berobenatide, its investigational GLP-1 receptor agonist, showing 15.9% non-placebo-adjusted weight loss with no plateau at 32 weeks. The company plans to advance 10 Phase 3 studies in 2026 for chronic weight management and obesity-related conditions. Additionally, the FDA approved an expanded indication for Pfizer's HYMPAVZI for hemophilia patients. PFE shares declined 1.3% to $25.70 at publication.